Venetoclax infectious risk score to identify patients with chronic lymphocytic leukemia at high infectious risk during venetoclax treatment: A multicenter SEIFEM study

被引：2
|
作者：
Autore, Francesco [1 ]
Visentin, Andrea [2 ]
Deodato, Marina [3 ]
Vitale, Candida [4 ,5 ]
Galli, Eugenio [1 ]
Fresa, Alberto [1 ]
Fazzi, Rita [6 ]
Sanna, Alessandro [7 ]
Olivieri, Jacopo [8 ]
Scortechini, Ilaria [9 ]
Del Principe, Maria Ilaria [10 ]
Sportoletti, Paolo [11 ]
Schiattone, Luana [12 ]
Maschio, Nilla [13 ]
Facchinelli, Davide [14 ]
Marchesi, Francesco [15 ]
Coscia, Marta [4 ,5 ]
Tedeschi, Alessandra [3 ]
Trentin, Livio [2 ]
Innocenti, Idanna [1 ]
Candoni, Anna [8 ,16 ]
Busca, Alessandro [4 ,5 ]
Pagano, Livio [1 ]
Laurenti, Luca [1 ]
机构：
[1] Fdn Policlin Univ A Gemelli IRCCS, Largo Agostino Gemelli 8, I-00168 Rome, Italy
[2] Univ Padua, Padua, Italy
[3] ASST Grande Osped Metropolitano Niguarda, Milan, Italy
[4] Univ Torino, AOU Citta Salute & Sci Torino, Turin, Italy
[5] Univ Torino, Dipartimento Biotecnol Mol & Sci Salute, Turin, Italy
[6] Azienda Osped Univ Pisana, Pisa, Italy
[7] Azienda Osped Univ Careggi, Florence, Italy
[8] Clin Ematol Udine, Udine, Italy
[9] Azienda Osped Univ Marche, Ancona, Italy
[10] Univ Roma Tor Vergata, Dipartimento Biomed & Prevenz, Rome, Italy
[11] AO Santa Maria Misericordia Perugia, Perugia, Italy
[12] Presidio Osped S Spirito Pescara, Pescara, Italy
[13] Oncoematol Ist Oncol Veneto IOV IRCCS, Padua, Italy
[14] Osped San Bortolo, Vicenza, Italy
[15] IRCCS Regina Elena Natl Canc Inst, Rome, Italy
[16] Univ Modena & Reggio Emilia, Modena, Italy
来源：
AMERICAN JOURNAL OF HEMATOLOGY | 2024年 / 99卷 / 05期
关键词：
RITUXIMAB;
D O I：
10.1002/ajh.27247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：982 / 984
页数：3
相关论文
共 50 条
  • [21] High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia
    Al-Sawaf, Othman
    Lilienweiss, Esther
    Bahlo, Jasmin
    Robrecht, Sandra
    Fink, Anna-Maria
    Patz, Michaela
    Tandon, Maneesh
    Jiang, Yanwen
    Schary, William
    Ritgen, Matthias
    Tausch, Eugen
    Stilgenbauer, Stephan
    Eichhorst, Barbara
    Fischer, Kirsten
    Hallek, Michael
    Kreuzer, Karl-Anton
    BLOOD, 2020, 135 (11) : 866 - 870
  • [22] Genomic arrays identify high-risk chronic lymphocytic leukemia with genomic complexity: a multicenter study
    Leeksma, Alexander C.
    Baliakas, Panagiotis
    Moysiadis, Theodoros
    Puiggros, Anna
    Plevova, Karla
    van der Kevie-Kersemaekers, Anne-Marie
    Posthuma, Hidde
    Rodriguez-Vicente, Ana E.
    Tran, Anh Nhi
    Barbany, Gisela
    Mansouri, Larry
    Gunnarsson, Rebeqa
    Parker, Helen
    van den Berg, Eva
    Bellido, Mar
    Davis, Zadie
    Wall, Meaghan
    Scarpelli, Ilaria
    Osterborg, Anders
    Hansson, Lotta
    Jarosova, Marie
    Ghia, Paolo
    Poddighe, Pino
    Espinet, Blanca
    Pospisilova, Sarka
    Tam, Constantine
    Ysebaert, Loic
    Nguyen-Khac, Florence
    Oscier, David
    Haferlach, Claudia
    Schoumans, Jacqueline
    Stevens-Kroef, Marian
    Eldering, Eric
    Stamatopoulos, Kostas
    Rosenquist, Richard
    Strefford, Jonathan C.
    Mellink, Clemens
    Kater, Arnon P.
    HAEMATOLOGICA, 2021, 106 (01) : 87 - 97
  • [23] NURSING IMPLICATIONS FOR VENETOCLAX USE IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A MULTICENTER ANALYSIS
    Kennard, Kaitlin
    Howlett, Christina
    Timberg, Mary
    Staller, Emma
    Varga, Julia
    Dorsey, Colleen
    ONCOLOGY NURSING FORUM, 2018, 45 (02)
  • [24] Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk Disease
    Davids, Matthew S.
    Ryan, Christine E.
    Lampson, Benjamin L.
    Ren, Yue
    Tyekucheva, Svitlana
    Fernandes, Stacey M.
    Crombie, Jennifer L.
    Kim, Austin I.
    Weinstock, Matthew
    Montegaard, Josie
    Walker, Heather A.
    Greenman, Claire
    Patterson, Victoria
    Jacobson, Caron A.
    Lacasce, Ann S.
    Armand, Philippe
    Fisher, David C.
    Lo, Steve
    Olszewski, Adam J.
    Arnason, Jon E.
    Ahn, Inhye E.
    Brown, Jennifer R.
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (07)
  • [25] Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
    Curtis, Jeffrey R.
    Winthrop, Kevin
    O'Brien, Cathy
    Ndlovu, 'Matladi N.
    de Longueville, Marc
    Haraoui, Boulos
    ARTHRITIS RESEARCH & THERAPY, 2017, 19
  • [26] Use of a baseline risk score to identify the risk of serious infectious events in patients with rheumatoid arthritis during certolizumab pegol treatment
    Jeffrey R. Curtis
    Kevin Winthrop
    Cathy O’Brien
    Matladi N. Ndlovu
    Marc de Longueville
    Boulos Haraoui
    Arthritis Research & Therapy, 19
  • [27] USE OF A GLOBAL RISK SCORE TO IDENTIFY PATIENTS WITH RHEUMATOID ARTHRITIS AT RISK OF SERIOUS INFECTIOUS EVENTS DURING CERTOLIZUMAB PEGOL TREATMENT
    Curtis, J. R.
    Winthrop, K.
    de Longueville, M.
    O'Brien, C.
    Ndlovu, M. N.
    Haraoui, B.
    ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 230 - 230
  • [28] Tumor lysis syndrome and infectious complications during treatment with venetoclax combined with azacitidine or decitabine in patients with acute myeloid leukemia
    Arora, Sankalp
    Zainaldin, Carl
    Bathini, Srilakshmi
    Gupta, Udita
    Worth, Sarah
    Bachiashvili, Kimo
    Bhatia, Ravi
    Godby, Kelly
    Jamy, Omer
    Rangaraju, Sravanti
    Diamond, Barry
    Oliver, Josh D.
    Salzman, Donna
    Di Stasi, Antonio
    Vachhani, Pankit
    LEUKEMIA RESEARCH, 2022, 117
  • [29] Risk Model for Overall Survival for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Validated for Patients on Ibrutinib, Idelalisib, Venetoclax, or Chemoimmuniotheraphy
    Soumerai, Jacob D.
    Ni, Ai
    Darif, Mohamed
    Londhe, Anil
    Xing, Guan
    Mun, Yong
    Kay, Neil E.
    Shanafelt, Tait D.
    Chaffee, Kari G.
    Furman, Richard R.
    Hillmen, Peter
    Sharman, Jeff
    Seymour, John F.
    Chanan-Khan, Asher A.
    Byrd, John C.
    Jones, Jeffrey A.
    Ferrante, Lucille A.
    Dreiling, Lyndah K.
    Mobasher, Mehrdad
    Stark, Thomas
    Reddy, Vijay
    Howes, Angela J.
    James, Danelle
    Bhargava, Pankaj
    Zelenetz, Andrew D.
    BLOOD, 2018, 132
  • [30] Combined Ibrutinib and Venetoclax for First-Line Treatment for Patients with Chronic Lymphocytic Leukemia (CLL)
    Jain, Nitin
    Keating, Michael J.
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam M.
    Takahashi, Koichi
    Estrov, Zeev E.
    Fowler, Nathan H.
    Kadia, Tapan M.
    Konopleva, Marina Y.
    Alvarado, Yesid
    Yilmaz, Musa
    DiNardo, Courtney D.
    Bose, Prithviraj
    Ohanian, Maro
    Pemmaraju, Naveen
    Jabbour, Elias
    Sasaki, Koji
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Jorgensen, Jeffrey L.
    Wang, Sa A.
    Garg, Naveen
    Wang, Xuemei
    Sondermann, Katrina
    Cruz, Nichole
    Wei, Chongjuan
    Ayala, Ana
    Plunkett, William
    Kantarjian, Hagop M.
    Gandhi, Varsha
    Wierda, William G.
    BLOOD, 2019, 134
12345